Itziar Minchole
Overview
Explore the profile of Itziar Minchole including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
280
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Noureddin M, Truong E, Mayo R, Martinez-Arranz I, Minchole I, Banales J, et al.
Hepatology
. 2024 Sep;
81(1):E12-E16.
PMID: 39325967
No abstract available.
2.
Iruzubieta P, Mayo R, Minchole I, Martinez-Arranz I, Arias-Loste M, Ibanez-Samaniego L, et al.
United European Gastroenterol J
. 2024 Aug;
12(7):919-929.
PMID: 39099245
Background And Aim: Type 2 Diabetes mellitus (T2DM), age, and obesity are risk factors for metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to assess the performance of non-invasive tests...
3.
Martinez-Arranz I, Alonso C, Mayo R, Minchole I, Mato J, Lee D
Comput Methods Programs Biomed
. 2024 Aug;
255:108346.
PMID: 39089186
Background & Aims: We previously identified subsets of patients with metabolic (dysfunction)-associated steatotic liver disease (MASLD) with different metabolic phenotypes. Here, we aimed to refine this classification based on genetic...
4.
Noureddin M, Truong E, Mayo R, Martinez-Arranz I, Minchole I, Banales J, et al.
Hepatology
. 2023 Jul;
79(1):135-148.
PMID: 37505221
Background: Early identification of those with NAFLD activity score ≥ 4 and significant fibrosis (≥F2) or at-risk metabolic dysfunction-associated steatohepatitis (MASH) is a priority as these patients are at increased...
5.
Martinez-Arranz I, Bruzzone C, Noureddin M, Gil-Redondo R, Minchole I, Bizkarguenaga M, et al.
Hepatology
. 2022 Feb;
76(4):1121-1134.
PMID: 35220605
Background And Aims: We previously identified subsets of patients with NAFLD with different metabolic phenotypes. Here we align metabolomic signatures with cardiovascular disease (CVD) and genetic risk factors. Approach And...
6.
Mayo R, Crespo J, Martinez-Arranz I, Banales J, Arias M, Minchole I, et al.
Hepatol Commun
. 2018 Jul;
2(7):807-820.
PMID: 30027139
Nonalcoholic fatty liver disease (NAFLD) is the most common type of chronic liver disease worldwide and includes a broad spectrum of histologic phenotypes, ranging from simple hepatic steatosis or nonalcoholic...
7.
Alonso C, Fernandez-Ramos D, Varela-Rey M, Martinez-Arranz I, Navasa N, van Liempd S, et al.
Gastroenterology
. 2017 Jan;
152(6):1449-1461.e7.
PMID: 28132890
Background & Aims: Nonalcoholic fatty liver disease (NAFLD) is a consequence of defects in diverse metabolic pathways that involve hepatic accumulation of triglycerides. Features of these aberrations might determine whether...
8.
Martinez-Arranz I, Mayo R, Perez-Cormenzana M, Minchole I, Salazar L, Alonso C, et al.
Data Brief
. 2015 Jul;
3:155-64.
PMID: 26217737
Metabolomics research has evolved considerably, particularly during the last decade. Over the course of this evolution, the interest in this 'omic' discipline is now more evident than ever. However, the...
9.
Martinez-Arranz I, Mayo R, Perez-Cormenzana M, Minchole I, Salazar L, Alonso C, et al.
J Proteomics
. 2015 Feb;
127(Pt B):275-88.
PMID: 25668325
Biological Significance: Metabolomics is a discipline involving the analysis of a large amount of data to gather relevant information. Researchers in this field have to overcome the challenges of complex...